Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1326
Alpha and Omega Semiconductor
AOSL
$915M
| $12.1M | 0.01% |
889,700
-87,604
| -9% | -$1.11M |
|
1327
iRhythm Holdings
IRTC
$4.19B
| $12.1M | 0.01% |
+177,500
| New | +$12M |
|
|
GSB
1328
DELISTED
GlobalSCAPE, Inc.
GSB
| $12.1M | 0.01% |
1,228,390
+14,046
| +1% | +$152K |
|
1329
German American Bancorp
GABC
$1.93B
| $12M | 0.01% |
337,100
-12,300
| -4% | -$411K |
|
|
SEI
1330
Solaris Energy Infrastructure
SEI
$4.16B
| $11.9M | 0.01% |
853,575
+103,800
| +14% | +$1.25M |
|
1331
Antero Resources
AR
$11.5B
| $11.9M | 0.01% |
4,188,700
-228,097
| -5% | -$582K |
|
|
CEL
1332
DELISTED
Cellcom Israel, Ltd.
CEL
| $11.9M | 0.01% |
3,789,672
+21,695
| +0.6% | +$58.8K |
|
1333
Wipro
WIT
$19.3B
| $11.9M | 0.01% |
6,366,054
+87,520
| +1% | +$165K |
|
|
BLD
1334
DELISTED
TopBuild
BLD
| $11.9M | 0.01% |
115,400
+56,600
| +96% | +$5.89M |
|
1335
Teekay
TK
$1.08B
| $11.9M | 0.01% |
2,233,465
+329,400
| +17% | +$1.63M |
|
1336
iShares MBS ETF
MBB
$39.1B
| $11.9M | 0.01% |
109,845
+37,517
| +52% | +$4.05M |
|
|
BRT
1337
BRT Apartments
BRT
$270M
| $11.9M | 0.01% |
698,787
+66,245
| +10% | +$1.11M |
|
1338
LyondellBasell Industries
LYB
$20.6B
| $11.8M | 0.01% |
+125,400
| New | +$11.5M |
|
|
GLIBA
1339
DELISTED
GCI Liberty, Inc. Class A Common Stock (DE)
GLIBA
| $11.8M | 0.01% |
167,210
+157,800
| +1,677% | +$10.9M |
|
|
NTUS
1340
DELISTED
Natus Medical Inc
NTUS
| $11.8M | 0.01% |
358,945
+120,345
| +50% | +$3.86M |
|
|
HMTV
1341
DELISTED
Hemisphere Media Group, Inc.
HMTV
| $11.8M | 0.01% |
796,000
+18,200
| +2% | +$237K |
|
1342
Knowles
KN
$3.31B
| $11.8M | 0.01% |
556,674
+494,000
| +788% | +$10.6M |
|
|
HNGR
1343
DELISTED
Hanger Inc.
HNGR
| $11.8M | 0.01% |
425,862
-117,400
| -22% | -$2.79M |
|
1344
Maximus
MMS
$2.91B
| $11.8M | 0.01% |
158,000
+151,100
| +2,190% | +$11.4M |
|
1345
Imperial Oil
IMO
$65.2B
| $11.7M | 0.01% |
443,458
+147,958
| +50% | +$3.74M |
|
1346
Aurinia Pharmaceuticals
AUPH
$2.03B
| $11.7M | 0.01% |
578,534
+567,789
| +5,284% | +$5.23M |
|
1347
Cencora
COR
$59B
| $11.7M | 0.01% |
+137,700
| New | +$11.8M |
|
|
PTNR
1348
DELISTED
Partner Communications
PTNR
| $11.7M | 0.01% |
2,682,550
+4,000
| +0.1% | +$17.6K |
|
1349
eGain
EGAN
$205M
| $11.7M | 0.01% |
1,475,921
-14,200
| -1% | -$110K |
|
1350
Travere Therapeutics
TVTX
$5.75B
| $11.6M | 0.01% |
816,827
+135,902
| +20% | +$1.74M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.